IMCR Share Price Performance
US$33.73
3.48 (11.50%)
49.3% undervalued intrinsic discount
US$66.57
Fair Value
Price US$33.73
AnalystConsensusTarget US$66.57
AnalystHighTarget US$100.00
AnalystLowTarget US$37.00
Fair ValueUS$66.57
Share Pricen/a
Immunocore Holdings plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
IMCR Community Narratives
AN
Fair Value US$66.57 49.3% undervalued intrinsic discount
Aging Demographics And Late-Stage Trials Will Expand Global Markets
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$100 66.3% undervalued intrinsic discount
Declining Genomic Costs Will Expand Personalized Immunotherapies
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$37 8.8% undervalued intrinsic discount
European Price Controls Will Erode Immunotherapy Viability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Demographics And Late-Stage Trials Will Expand Global Markets
Key Takeaways Expanding therapeutic portfolio and successful market entry reduce reliance on a single product and support a foundation for future revenue growth. Strong pricing power, effective cost management, and increased payer reimbursement position the company for stable margins and operational flexibility.Read more
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$66.57
49.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
6.57%
Future PE
103.17x
Price in 2029
US$83.2
European Price Controls Will Erode Immunotherapy Viability
Key Takeaways Reliance on favorable drug pricing and a single lead product increases vulnerability to future regulatory and market shifts, risking income and growth stability. Escalating competition and regulatory hurdles threaten both technology relevance and clinical pipeline progress, undermining long-term commercial viability.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$37
8.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
16.05%
Future PE
28.75x
Price in 2029
US$45.82
Declining Genomic Costs Will Expand Personalized Immunotherapies
Key Takeaways Potential for much higher market penetration and revenue growth than consensus due to superior product tolerability and strong real-world performance. Broad, late-stage pipeline with diverse indications and platform advantages could drive significant earnings growth and strategic partnership or acquisition interest.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$100
66.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
11.64%
Future PE
83.1x
Price in 2028
US$123.05
Trending Discussion
Recently Updated Narratives
AN
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Fair Value: US$66.57 49.3% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Fair Value: US$37 8.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Declining Genomic Costs Will Expand Personalized Immunotherapies
Fair Value: US$100 66.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Immunocore Holdings plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.70
- 96.53%
- -8.88%
- 103.2%
About IMCR
- Founded
- 1999
- Employees
- 524
- CEO
- WebsiteView website
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
